z-logo
open-access-imgOpen Access
Leukocyte neutrophil ratio (NLR) as biomarker for neuroinflammation in patients with intracerebral haemorrhage and traumatic brain injury
Author(s) -
Amrita Ghosh,
AUTHOR_ID,
Ranabir Pal,
Rakesh Mishra,
Rafael Cincu,
Luís Rafael Moscote-Salazar,
Amit Agrawal,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2021
Publication title -
romanian journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 4
eISSN - 2069-6094
pISSN - 1843-8148
DOI - 10.37897/rjn.2021.3.5
Subject(s) - medicine , traumatic brain injury , neuroinflammation , delirium , coma (optics) , biomarker , glasgow coma scale , neutrophil to lymphocyte ratio , intensive care medicine , lymphocyte , anesthesia , inflammation , psychiatry , biochemistry , chemistry , physics , optics
Circulating inflammatory markers may predict the broad clinical spectrum of traumatic brain injury (TBI). The present study aimed to illustrate the role of leukocytes, precisely neutrophil and lymphocytes, in neuroinflammation as a new vista in neuro-critical care. Search terms were: elevations in peripheral blood leukocytes counts, neutrophil, lymphocyte with precisely neutrophil to lymphocyte ratios, associated with adverse outcomes of traumatic brain injury, pre and post-operative conditions of intracerebral haemorrhage, seizures, delirium, non-convulsive status epilepticus, confusion, aphasia, agitation, coma, disability and death. As a result, we identified 16 publications describing leukocyte biomarkers associated with neuroinflammation following TBI from PubMed, Cochrane Registry of Controlled Trials, Medline and Embase (Ovid) on randomised controlled trials (RCTs), non-RCTs and cohort studies published in the last decade. This study concluded that elevations in peripheral blood leukocyte and neutrophil to lymphocyte ratios could predict adverse outcomes of a cerebral haemorrhage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here